Researchers reported the link between aging, cancer, and epigenomic changes.
HF-158K1 by HighField Biopharmaceuticals for Uterine Cancer: Likelihood of Approval
HF-158K1 is under clinical development by HighField Biopharmaceuticals and currently in Phase I for Uterine Cancer.